All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

  TRANSLATE

The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Johnson & Johnson, and Syndax, and has been supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given.  View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

What is the impact of venetoclax combinations on the QoL of unfit, elderly patients with AML?

Featured:

Keith PratzKeith Pratz

Dec 22, 2020


During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub spoke to Keith Pratz, University of Pennsylvania, Philadelphia, US, about the impact of venetoclax combinations on the quality of life (QoL) of unfit, elderly patients with AML.

What is the impact of venetoclax combinations on the QoL of unfit, elderly patients with AML?

In this video, Pratz discusses the results of a study evaluating the impact of venetoclax addition to azacitidine (Viale-A study) or low-dose cytarabine (Viale-C study) on QoL, irrespective of response to therapy.

Your opinion matters

How important to you is the turnaround time for genetic testing in guiding your initial treatment decisions?